Product Description
Anti-viral RNA vaccine for active immunization against COVID-19
Mechanisms of Action: Vaccine
Novel Mechanism: No
Modality: Vaccine
Route of Administration: Intramuscular
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: BioNTech
Company Location: Europe
Company Founding Year: 2008
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: COVID-19
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2020-001038-36 |
Phase I/II Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-19 | P2 |
Completed |
COVID-19 |
2022-04-13 |
12% |
2022-03-13 |
Treatments |